CDC-RFA-JG-26-0125: Strengthening tuberculosis (TB) prevention, diagnosis, treatment, and surveillance in Asia
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control-GHC notices from 2026.
Centers for Disease Control-GHC offered grants to any type of organization. It expected to make about 3 awards. Applications closed on June 22, 2026.
From the official notice on Grants.gov, last changed May 22, 2026. Checked November 7, 2026.
- Expected awards3
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 22, 2026 |
|---|---|
| Deadline | June 22, 2026 |
| Archived by Grants.gov | August 24, 2026 |
Who can apply
This opportunity was open to any type of organization.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $3,000,000 for Year 1, subject to the availability of funds. The purpose of this NOFO is to reduce TB-related morbidity and mortality in India, the Philippines, and Vietnam by strengthening:• TB case finding, including linked activities such as screening, testing, and diagnostic evaluation.• TB prevention, including TB preventive treatment (TPT).• TB treatment, including linkage and improved treatment regimens, as appropriate.• Surveillance, through adopting, evaluating, and expanding innovative approaches. Activities implemented will focus on:• Expanding and improving diagnosis of TB infection and TB disease, including early and asymptomatic TB as well as drug-resistant or multidrug-resistant TB. This will be done by using and evaluating innovative screening and diagnostic methods and scaling up evidence-based approaches. • Improving TPT outcomes for all individuals at high risk of developing TB disease and improving TB treatment outcomes of individuals with TB disease, including those with drug-resistant or multidrug-resistant TB. This will be done by using new, shorter, and better-tolerated treatment regimens.• Strengthening TB surveillance for data-driven decision making, program planning, and public health action. Asia carries the highest burden of TB and drug-resistant or multidrug-resistant TB globally. This NOFO will focus on activities in India, the Philippines, and Vietnam because they are three of the top four countries contributing to the TB burden in the U.S. This aligns with the America First Global Health Strategy.
Who has won Global Tuberculosis:Developing,Evaluating,Implementing Evidence-based and Innovative Approaches to Find, Cure, and Prevent Tuberculosis Globally grants before
From fiscal 2021 to 2025, Global Tuberculosis:Developing,Evaluating,Implementing Evidence-based and Innovative Approaches to Find, Cure, and Prevent Tuberculosis Globally (93.494) awarded $18.4 million across 14 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Baylor College of Medicine | Texas | 1 | $5.3 million |
| United Nations Office for Project Services | 1 | $4.2 million | |
| Path | Washington | 1 | $2.7 million |
| World Health Organization, Somalia | 1 | $1.3 million | |
| Union Internat Tuberculose Maladie Respi | 1 | $1.3 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-JG-26-0125 still open?
No. It closed on June 22, 2026.
Who can apply for Strengthening tuberculosis (TB) prevention, diagnosis, treatment, and surveillance in Asia?
Centers for Disease Control-GHC accepted applications from any type of organization.
What is the deadline for Strengthening tuberculosis (TB) prevention, diagnosis, treatment, and surveillance in Asia?
Closed June 22, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Global Tuberculosis:Developing,Evaluating,Implementing Evidence-based and Innovative Approaches to Find, Cure, and Prevent Tuberculosis Globally grants before?
The largest recipients over five fiscal years were Baylor College of Medicine, United Nations Office for Project Services, Path. The program made 14 awards worth $18.4 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)